Child-Safe mpox vaccine trial shows promise for young ones
NCT ID NCT06549530
First seen Nov 24, 2025 · Last updated May 20, 2026 · Updated 24 times
Summary
This study tests the MVA-BN vaccine in 460 children aged 2 to 12 years to see if it safely prevents smallpox, mpox, and similar infections. Children receive two doses four weeks apart, and their immune response is compared to adults. The goal is to ensure the vaccine works and is safe for younger populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX (MPOX) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Epicentre Mbarara Research Centre
Mbarara, Uganda
-
Uganda Virus Research Institute
Entebbe, Uganda
-
University of Kinshasa
Kinshasa, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.